Literature DB >> 28498967

Surgical resection after neoadjuvant chemoradiation for oesophageal adenocarcinoma: what is the optimal timing?

David N Ranney1, Michael S Mulvihill1, Babatunde A Yerokun1, Zachary Fitch1, Zhifei Sun1, Chi-Fu Yang1, Thomas A D'Amico1, Matthew G Hartwig1.   

Abstract

OBJECTIVES: The purpose of this study was to determine the optimal timing of surgical resection of oesophageal adenocarcinoma following neoadjuvant chemoradiotherapy (nCRT).
METHODS: nCRT before resection of oesophageal adenocarcinoma yields improved overall and progression-free survival. Despite the wide acceptance of tri-modal therapy, the optimal timing of surgical resection after nCRT is not well defined and existing studies are limited. Adults with Stage II/III oesophageal adenocarcinoma undergoing nCRT before surgery were identified from the National Cancer Database. Multivariable analysis using restricted cubic splines was used to identify an inflection point in clinical outcomes as a function of time between nCRT and surgery, dividing the cohort into short- and long-interval treatment groups, which were then compared. Adjusted rates of survival and margin status were compared between groups using multivariable analysis.
RESULTS: Among 2444 patients, restricted cubic splines identified an inflection point at 56 days, dividing our cohort into 1533 short-interval and 911 long-interval patients. Long-interval patients had a higher adjusted incidence of pathologic downstaging (odds ratio 1.38, confidence interval 1.02-1.85, P = 0.04) but no difference in margin positivity compared with short-interval patients (odds ratio 0.91, confidence interval 0.56-1.47, P = 0.69). Worse overall survival was noted in the long-interval subgroup (hazard ratio 1.44, confidence interval 1.22-1.71, P < 0.001), but 30-day postoperative mortality was not statistically different (odds ratio 1.56, confidence interval 0.9-2.72, P = 0.12).
CONCLUSIONS: Restricted cubic splines provides an objective mechanism to more accurately delineate optimum timing between nCRT and surgical resection. A time interval of 56 days represents an interval where increased pathologic downstaging is balanced by decreased overall survival.
© The Author 2017. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  Neoadjuvant ; Oesophageal cancer ; Oesophagus ; Resection ; Timing

Mesh:

Year:  2017        PMID: 28498967     DOI: 10.1093/ejcts/ezx132

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  9 in total

1.  When to resect following neoadjuvant therapy for esophageal cancer-issues and limitations in addressing this decision.

Authors:  Emmanuel Gabriel; Steven N Hochwald
Journal:  J Thorac Dis       Date:  2017-08       Impact factor: 2.895

2.  Esophageal resection after neoadjuvant therapy: understanding the limitations of large database analyses.

Authors:  David N Ranney; Michael S Mulvihill; Babatunde A Yerokun; Matthew G Hartwig
Journal:  J Thorac Dis       Date:  2017-10       Impact factor: 2.895

Review 3.  Considerations for the Surgical Management of Thoracic Cancers During the COVID-19 Pandemic: Rational Strategies for Thoracic Surgeons.

Authors:  Jiahao Zhang; Yichao Han; Yajie Zhang; Dong Dong; Yuqin Cao; Xiang Chen; Hecheng Li
Journal:  Front Surg       Date:  2022-05-09

4.  The Effect of Timing of Adjuvant Therapy on Survival After Esophagectomy.

Authors:  Kristen E Rhodin; Vignesh Raman; Oliver K Jawitz; Betty C Tong; David H Harpole; Thomas A D'Amico
Journal:  Ann Thorac Surg       Date:  2020-04-21       Impact factor: 4.330

5.  From the completion of neoadjuvant chemotherapy to surgery for colorectal cancer liver metastasis: What is the optimal timing?

Authors:  Qichen Chen; Rui Mao; Jianjun Zhao; Xinyu Bi; Zhiyu Li; Zhen Huang; Yefan Zhang; Jianguo Zhou; Hong Zhao; Jianqiang Cai
Journal:  Cancer Med       Date:  2020-09-04       Impact factor: 4.452

6.  Time to surgery in thoracic cancers and prioritization during COVID-19: a systematic review.

Authors:  Scott C Fligor; Savas T Tsikis; Sophie Wang; Ana Sofia Ore; Benjamin G Allar; Ashlyn E Whitlock; Rodrigo Calvillo-Ortiz; Kevin Arndt; Mark P Callery; Sidhu P Gangadharan
Journal:  J Thorac Dis       Date:  2020-11       Impact factor: 2.895

Review 7.  The Key Clinical Questions of Neoadjuvant Chemoradiotherapy for Resectable Esophageal Cancer-A Review.

Authors:  Dan Han; Baosheng Li; Qian Zhao; Hongfu Sun; Jinling Dong; Shaoyu Hao; Wei Huang
Journal:  Front Oncol       Date:  2022-07-14       Impact factor: 5.738

8.  Timing of surgery after neoadjuvant chemotherapy for gastric cancer: Impact on outcomes.

Authors:  Yi Liu; Ke-Cheng Zhang; Xiao-Hui Huang; Hong-Qing Xi; Yun-He Gao; Wen-Quan Liang; Xin-Xin Wang; Lin Chen
Journal:  World J Gastroenterol       Date:  2018-01-14       Impact factor: 5.742

9.  Association between time interval from neoadjuvant chemoradiotherapy to surgery and complete histological tumor response in esophageal and gastroesophageal junction cancer: a national cohort study.

Authors:  F Klevebro; K Nilsson; M Lindblad; S Ekman; J Johansson; L Lundell; N Ndegwa; J Hedberg; M Nilsson
Journal:  Dis Esophagus       Date:  2020-05-15       Impact factor: 3.429

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.